HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SUPN

Supernus Pharmaceuticals Inc

Last Close
Dec 24 • 04:00PM ET
35.60
Dollar change
+0.01
Percentage change
0.03 		%
Healthcare • Drug Manufacturers - Specialty & Generic • USA • NASD
Peers: NBIX ACAD TEVA UTHR INSM AXNX PTCT DRRX MNKD XENE
 | Held by: IJR VTI CALF IWM VB VBR AVUV VXF SPSM IWN
Scroll to Statements
IndexRUT P/E33.33 EPS (ttm)1.07 Insider Own4.24% Shs Outstand55.22M Perf Week-1.71%
Market Cap1.97B Forward P/E18.80 EPS next Y1.89 Insider Trans-12.83% Shs Float52.88M Perf Month-1.71%
Income59.71M PEG19.72 EPS next Q0.50 Inst Own110.45% Short Float12.55% Perf Quarter18.90%
Sales651.97M P/S3.02 EPS this Y21.50% Inst Trans2.93% Short Ratio19.38 Perf Half Y33.23%
Book/sh18.24 P/B1.95 EPS next Y-33.72% ROA4.54% Short Interest6.64M Perf Year21.79%
Cash/sh7.30 P/C4.88 EPS next 5Y1.69% ROE6.22% 52W Range25.53 - 39.37 Perf YTD23.01%
Dividend Est.- P/FCF11.43 EPS past 5Y-59.02% ROI5.76% 52W High-9.58% Beta0.90
Dividend TTM- Quick Ratio1.98 Sales past 5Y9.22% Gross Margin76.28% 52W Low39.44% ATR (14)1.14
Dividend Ex-Date- Current Ratio2.20 EPS Y/Y TTM128.31% Oper. Margin11.16% RSI (14)45.41 Volatility3.46% 2.97%
Employees652 Debt/Eq0.04 Sales Y/Y TTM6.79% Profit Margin9.16% Recom2.00 Target Price39.25
Option/ShortYes / Yes LT Debt/Eq0.03 EPS Q/Q334.94% Payout0.00% Rel Volume0.36 Prev Close35.59
Sales Surprise11.66% EPS Surprise163.57% Sales Q/Q14.17% EarningsNov 04 AMC Avg Volume342.57K Price35.60
SMA20-2.27% SMA50-0.22% SMA20011.75% Trades Volume125,303 Change0.03%
Date Action Analyst Rating Change Price Target Change
Sep-11-24Downgrade Piper Sandler Overweight → Neutral $41 → $36
Jan-03-23Resumed Jefferies Buy $44 → $45
Dec-01-21Resumed Jefferies Buy $40 → $44
Apr-13-21Upgrade Jefferies Hold → Buy $25 → $40
Jun-16-20Upgrade Piper Sandler Neutral → Overweight $25 → $31
Jun-15-20Resumed Jefferies Hold $24
Nov-08-19Downgrade Berenberg Buy → Hold
Nov-07-19Downgrade Stifel Buy → Hold $55 → $23
Nov-06-19Downgrade Jefferies Buy → Hold $46 → $23
Nov-12-18Reiterated B. Riley FBR Buy $68 → $65
Show Previous Ratings
Dec-16-24 04:30PM
Knight Therapeutics Announces Filing of New Drug Submission for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Nov-26-24 05:00PM
Supernus to Participate in the 36th Annual Piper Sandler Healthcare Conference
(GlobeNewswire)
Nov-13-24 04:30PM
Supernus Pharmaceuticals to Participate in the 2024 Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-05-24 08:00AM
Supernus Pharmaceuticals Inc (SUPN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Nov-04-24 08:00PM
Supernus (SUPN) Reports Q3 Earnings: What Key Metrics Have to Say
(Zacks)
07:35PM Loading…
07:35PM
Supernus Pharmaceuticals (SUPN) Beats Q3 Earnings and Revenue Estimates
(Zacks)
06:33PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-31-24 04:10PM
Supernus Presents Promising Data from Open-Label Phase 2a Study of SPN-820 Data in Major Depressive Disorder at Psych Congress 2024
(GlobeNewswire)
Oct-21-24 04:25PM
Supernus Pharmaceuticals to Host Conference Call and Webcast on November 4, 2024 to Discuss Third Quarter 2024 Financial Results
(GlobeNewswire)
Oct-18-24 08:31PM
Supernus depression drug improved symptoms in two hours in Phase IIa study
(Clinical Trials Arena)
Oct-17-24 04:05PM
Supernus Announces Promising Data from Open-Label Phase 2a Study of SPN-820 in Adults with Major Depressive Disorder
(GlobeNewswire)
Oct-10-24 05:12PM
Supernus Pharmaceuticals to Host Webcast to Review Open-Label Phase 2a Study of SPN-820 for the Treatment of Major Depressive Disorder
(GlobeNewswire)
Oct-09-24 05:07PM
Supernus Pharmaceuticals Inc (SUPN) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
(GuruFocus.com)
Sep-24-24 07:30AM
Busy Philipps Encourages Women to Take Charge of Their ADHD This Fall in Ongoing Collaboration with Supernus Pharmaceuticals and Qelbree
(GlobeNewswire)
04:30PM Loading…
Sep-19-24 04:30PM
Supernus Pharmaceuticals to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit
(GlobeNewswire)
Sep-16-24 10:50AM
Supernus Pharmaceuticals (SUPN) Slid on Disappointing Progress Report on a Key Drug
(Insider Monkey)
Sep-11-24 02:38PM
ADHD Drug Maker Supernus Pharmaceuticals Downgraded On Slower Prescription Growth For Its Top-Selling Drug
(Benzinga) -7.20%
Aug-28-24 04:15PM
Supernus Pharmaceuticals to Participate in the 2024 Wells Fargo Healthcare Conference
(GlobeNewswire)
Aug-19-24 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Aug-09-24 09:55AM
Does Supernus (SUPN) Have the Potential to Rally 28.65% as Wall Street Analysts Expect?
(Zacks)
Aug-06-24 08:00PM
Supernus (SUPN) Reports Q2 Earnings: What Key Metrics Have to Say
(Zacks) +14.49%
06:45PM
Supernus Pharmaceuticals (SUPN) Misses Q2 Earnings Estimates
(Zacks)
05:36PM
Supernus: Q2 Earnings Snapshot
(Associated Press Finance)
04:06PM
Supernus Announces Second Quarter 2024 Financial Results
(GlobeNewswire)
Aug-01-24 04:30PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Jul-23-24 04:13PM
Supernus Pharmaceuticals to Announce Second Quarter 2024 Financial Results and Host Conference Call on August 6, 2024
(GlobeNewswire)
Jul-19-24 01:58PM
If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names
(InvestorPlace)
May-30-24 04:25PM
Supernus Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
(GlobeNewswire)
May-24-24 11:53AM
Do Options Traders Know Something About Supernus (SUPN) Stock We Don't?
(Zacks)
04:05PM Loading…
May-23-24 04:05PM
Supernus Announces Promising Interim Data from Ongoing Open-Label Phase 2a Study of SPN-817 in Epilepsy
(GlobeNewswire)
May-10-24 01:38PM
Supernus Pharmaceuticals Reports Mixed Q1 2024 Results Amidst Strategic Shifts and Pipeline ...
(GuruFocus.com)
May-09-24 04:05PM
Supernus Pharmaceuticals to Host Webcast to Review Interim Data from Ongoing Open-Label Phase IIa Study of SPN-817 for Treatment-Resistant Seizures
(GlobeNewswire)
11:56AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2024 Earnings Call Transcript
(Insider Monkey)
03:42AM
Supernus Pharmaceuticals Inc (SUPN) Q1 2024 Earnings Call Transcript Highlights: Navigating ...
(GuruFocus.com)
May-08-24 10:56PM
SUPN Stock Earnings: Supernus Pharmaceuticals Misses Revenue for Q1 2024
(InvestorPlace)
07:00PM
Compared to Estimates, Supernus (SUPN) Q1 Earnings: A Look at Key Metrics
(Zacks)
04:05PM
Supernus Announces First Quarter 2024 Financial Results
(GlobeNewswire)
May-07-24 11:46AM
Supernus, M8 Pharmaceuticals Sign Licensing Deal for ADHD Drug Qelbree in Latin America
(MT Newswires)
10:00AM
M8 Pharmaceuticals, an Acino company, signs an exclusive licensing agreement with Supernus for Qelbree (Viloxazine XR) in Latin America
(PR Newswire)
09:15AM
Ahead of Supernus (SUPN) Q1 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
May-01-24 08:00AM
Busy Philipps Shines Spotlight on ADHD in Women and Shares her Qelbree Story
(GlobeNewswire)
Apr-24-24 04:05PM
Supernus Pharmaceuticals to Announce First Quarter 2024 Financial Results and Host Conference Call on May 8, 2024
(GlobeNewswire)
Apr-08-24 12:11PM
Supernus Pharmaceuticals Faces Second FDA Rejection For Investigational Device For Parkinson's Disease
(Benzinga) -6.32%
08:00AM
Supernus Provides Regulatory Update for SPN-830
(GlobeNewswire)
Mar-27-24 04:37PM
Corporate Insiders Are Selling These 10 Small-Cap Stocks
(Insider Monkey)
Mar-06-24 04:30PM
Supernus to Participate in Two Upcoming Investor Conferences
(GlobeNewswire)
Mar-04-24 08:28PM
11 Best Small Cap Pharma Stocks to Invest In
(Insider Monkey)
Feb-28-24 04:30PM
Supernus to Participate in the TD Cowen 44th Annual Healthcare Conference
(GlobeNewswire)
09:19AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q4 2023 Earnings Call Transcript
(Insider Monkey)
07:17AM
Q4 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents)
Feb-27-24 07:30PM
Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say
(Zacks)
06:50PM
Supernus Pharmaceuticals (SUPN) Lags Q4 Earnings Estimates
(Zacks)
06:02PM
Supernus: Q4 Earnings Snapshot
(Associated Press Finance)
05:00PM
Supernus Pharmaceuticals Inc (SUPN) Reports Robust Growth in Key Products for Full Year 2023
(GuruFocus.com)
04:05PM
Supernus Announces Fourth Quarter and Full Year 2023 Financial Results
(GlobeNewswire)
Feb-26-24 09:15AM
Ahead of Supernus (SUPN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
(Zacks)
Feb-20-24 10:00AM
Analysts Estimate Supernus Pharmaceuticals (SUPN) to Report a Decline in Earnings: What to Look Out for
(Zacks)
Feb-13-24 04:05PM
Supernus Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call on February 27, 2024
(GlobeNewswire)
Feb-05-24 08:30AM
Supernus Wins Infringement and Validity Case on Trokendi XR against Torrent
(GlobeNewswire)
Dec-19-23 07:30AM
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada
(GlobeNewswire)
Dec-14-23 07:43PM
Mind-Bending Growth: 3 Psychedelic Stocks With Trippy Potential
(InvestorPlace)
Nov-18-23 05:03AM
Insider Sell Alert: Director Frederick Hudson Sells 9,093 Shares of Supernus Pharmaceuticals ...
(GuruFocus.com)
Nov-10-23 12:10PM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q3 2023 Earnings Call Transcript
(Insider Monkey)
Nov-09-23 09:54AM
Q3 2023 Supernus Pharmaceuticals Inc Earnings Call
(Thomson Reuters StreetEvents) +11.14%
Nov-08-23 07:30PM
Supernus (SUPN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
(Zacks)
07:15PM
Supernus Pharmaceuticals (SUPN) Reports Q3 Loss, Tops Revenue Estimates
(Zacks)
06:08PM
Supernus: Q3 Earnings Snapshot
(Associated Press Finance)
04:05PM
Supernus Announces Third Quarter 2023 Financial Results
(GlobeNewswire)
Nov-07-23 04:30PM
Supernus to Participate in the Jefferies London Healthcare Conference
(GlobeNewswire)
Nov-02-23 07:00AM
Supernus Announces SPN-830 Apomorphine Infusion Device NDA Accepted for Review by FDA
(GlobeNewswire)
Nov-01-23 10:01AM
Supernus Pharmaceuticals (SUPN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
(Zacks)
Oct-25-23 04:15PM
Supernus Pharmaceuticals to Announce Third Quarter 2023 Financial Results and Host Conference Call on November 8, 2023
(GlobeNewswire)
Oct-16-23 05:34PM
Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey
(GlobeNewswire)
Oct-09-23 04:45PM
Supernus Resubmits NDA for SPN-830 Apomorphine Infusion Device
(GlobeNewswire)
Sep-27-23 04:15PM
Supernus Pharmaceuticals Announces Webcast of R&D Day to be Held on October 18, 2023 in New York City
(GlobeNewswire)
Sep-26-23 07:37PM
Supernus Pharmaceuticals (SUPN): A Hidden Gem in the Market? A Comprehensive Analysis of Its ...
(GuruFocus.com)
Sep-09-23 08:00PM
Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms
(GlobeNewswire)
Aug-31-23 05:30PM
Supernus to Participate in the Wells Fargo Healthcare Conference
(GlobeNewswire)
Aug-21-23 09:00AM
Bethany L. Sensenig Joins Supernus Board of Directors
(GlobeNewswire)
Aug-08-23 08:30PM
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
(Zacks) -7.23%
07:55PM
Supernus Pharmaceuticals (SUPN) Reports Q2 Loss, Misses Revenue Estimates
(Zacks)
06:40PM
Supernus: Q2 Earnings Snapshot
(AP Finance)
04:17PM
Supernus Announces Second Quarter 2023 Financial Results
(GlobeNewswire)
Jul-28-23 02:56PM
10 Best Small Cap Pharma Stocks to Buy
(Insider Monkey)
Jul-25-23 06:36AM
Does The Market Have A Low Tolerance For Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Mixed Fundamentals?
(Simply Wall St.)
Jul-24-23 04:05PM
Supernus Pharmaceuticals to Announce Second Quarter 2023 Financial Results and Host Conference Call on August 8, 2023
(GlobeNewswire)
Jun-27-23 11:50AM
The five-year shareholder returns and company earnings persist lower as Supernus Pharmaceuticals (NASDAQ:SUPN) stock falls a further 9.4% in past week
(Simply Wall St.)
Jun-21-23 08:00PM
SUPN: What does Argus have to say about SUPN?
(Argus Research)
Jun-10-23 07:40AM
Despite 1 Major Headwind and Pricey Shares, This Stock Is Still a Buy
(Motley Fool)
May-31-23 04:15PM
Supernus to Participate in the Jefferies Healthcare Conference
(GlobeNewswire)
May-11-23 08:39AM
Top Healthcare Stocks for May 2023
(Investopedia)
May-10-23 11:23AM
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Q1 2023 Earnings Call Transcript
(Insider Monkey)
May-09-23 08:30PM
Supernus (SUPN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
(Zacks)
07:05PM
Supernus Pharmaceuticals (SUPN) Q1 Earnings and Revenues Beat Estimates
(Zacks)
06:09PM
Supernus: Q1 Earnings Snapshot
(AP Finance)
04:05PM
Supernus Announces First Quarter 2023 Financial Results
(GlobeNewswire)
May-02-23 04:05PM
Supernus to Present at the Bank of America 2023 Health Care Conference
(GlobeNewswire)
Apr-26-23 08:00PM
SUPN: What does Argus have to say about SUPN?
(Argus Research)
Apr-25-23 04:15PM
Supernus Pharmaceuticals to Announce First Quarter 2023 Financial Results and Host Conference Call on May 9, 2023
(GlobeNewswire)
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. It offers Trokendi XR, Oxtellar XR, APOKYN, XADAGO, and MYOBLOC products. The company was founded by Jack A. Khattar on March 30, 2005, and is headquartered in Rockville, MD.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Option Exercise24.7721,495532,36122,424Dec 04 04:36 PM
Bhatt Padmanabh P.Sr. VP of IP, CSODec 03 '24Sale36.6821,495788,4379,679Dec 04 04:36 PM
PADMANABH P BHATTOfficerDec 03 '24Proposed Sale37.3121,495801,978Dec 03 04:31 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Option Exercise9.1320,000182,600140,975Nov 12 04:15 PM
NEWHALL CHARLES W IIIDirectorNov 11 '24Sale36.2410,700387,768130,275Nov 12 04:15 PM
Hudson Frederick M.DirectorNov 08 '24Sale36.288,722316,43428,395Nov 12 04:14 PM
GEMAYEL GEORGESDirectorNov 08 '24Option Exercise11.4610,787123,61924,102Nov 12 04:13 PM
GEMAYEL GEORGESDirectorNov 08 '24Sale36.3010,787391,56813,315Nov 12 04:13 PM
Khattar Jack A.President, CEONov 08 '24Option Exercise9.13125,0001,141,2501,051,172Nov 12 04:11 PM
Khattar Jack A.President, CEONov 08 '24Sale36.29125,0004,536,250926,172Nov 12 04:11 PM
CHARLES NEWHALLOfficerNov 11 '24Proposed Sale36.2410,700387,775Nov 12 09:18 AM
JACK A KHATTAROfficerNov 08 '24Proposed Sale36.29125,0004,535,850Nov 08 05:00 PM
FREDERICK M HUDSONDirectorNov 08 '24Proposed Sale36.288,722316,476Nov 08 04:33 PM
GEORGES GEMAYELDirectorNov 08 '24Proposed Sale36.3010,787391,536Nov 08 04:19 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Option Exercise9.1315,000136,95023,200Nov 08 04:13 PM
Mottola FrankSVP, Quality, GMP, Ops, ITNov 07 '24Sale36.9815,000554,7008,200Nov 08 04:13 PM
GEMAYEL GEORGESDirectorNov 07 '24Option Exercise11.4614,213162,88127,528Nov 08 04:11 PM
GEMAYEL GEORGESDirectorNov 07 '24Sale36.6214,213520,48013,315Nov 08 04:11 PM
Khattar Jack A.President, CEONov 07 '24Option Exercise9.13125,0001,141,2501,051,172Nov 08 04:08 PM
Khattar Jack A.President, CEONov 07 '24Sale36.68125,0004,585,000926,172Nov 08 04:08 PM
JACK A KHATTAROfficerNov 07 '24Proposed Sale36.68125,0004,584,600Nov 07 04:59 PM
FRANK MOTTOLAOfficerNov 07 '24Proposed Sale36.9815,000554,692Nov 07 04:55 PM
GEORGES GEMAYELDirectorNov 07 '24Proposed Sale36.6214,213520,511Nov 07 04:42 PM
GEMAYEL GEORGESDirectorSep 13 '24Option Exercise11.4610,000114,60023,315Sep 17 04:10 PM
GEMAYEL GEORGESDirectorSep 13 '24Sale31.3313,886435,04813,315Sep 17 04:10 PM
GEORGES GEMAYELDirectorSep 13 '24Proposed Sale31.3313,886435,041Sep 13 04:30 PM
Khattar Jack A.President, CEOSep 03 '24Option Exercise0.0021,0000936,217Sep 03 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOAug 20 '24Option Exercise0.001,250010,251Aug 20 05:00 PM
TAMI TILLOTSON MARTINFormer OfficerAug 02 '24Proposed Sale29.024,000116,074Aug 02 04:16 PM
TAMI TILLOTSON MARTINFormer OfficerAug 01 '24Proposed Sale29.313,10090,856Aug 01 04:19 PM
TAMI TILLOTSON MARTINFormer OfficerJul 31 '24Proposed Sale30.135,000150,650Jul 31 04:41 PM
TAMI TILLOTSON MARTINFormer OfficerJul 30 '24Proposed Sale30.562,90088,610Jul 30 04:02 PM
TAMI TILLOTSON MARTINFormer OfficerJul 29 '24Proposed Sale30.755,000153,750Jul 29 04:08 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 21 '24Option Exercise25.3014,491366,62223,061Mar 25 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 21 '24Sale35.3114,491511,6778,570Mar 25 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 20 '24Option Exercise25.3040010,1208,970Mar 22 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 20 '24Sale35.3140014,1248,570Mar 22 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 19 '24Option Exercise25.3012,364312,80920,934Mar 21 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 19 '24Sale35.3112,364436,5738,570Mar 21 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 13 '24Option Exercise17.6162,3661,098,52344,686Mar 15 06:39 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 13 '24Sale33.7462,3662,104,2898,570Mar 15 06:39 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 12 '24Option Exercise12.983,88450,41412,454Mar 14 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOMar 12 '24Sale32.993,884128,1338,570Mar 14 05:00 PM
Mottola FrankSVP, Quality, GMP, Ops, ITFeb 28 '24Option Exercise0.0099008,239Feb 29 05:01 PM
Khattar Jack A.President, CEOFeb 28 '24Option Exercise0.0035,0000932,005Feb 29 05:00 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 26 '24Option Exercise9.135,00045,65013,570Feb 28 05:01 PM
Bhatt Padmanabh P.Sr. VP of IP, CSOFeb 26 '24Sale30.215,000151,0508,570Feb 28 05:01 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsJan 10 '24Option Exercise9.248,00073,92093,664Jan 12 05:00 PM
Martin Tami TillotsonSr. V.P., Regulatory AffairsJan 10 '24Sale27.918,000223,28085,664Jan 12 05:00 PM
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.